{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9"},{"groupId":"OG001","value":"89.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"259"},{"groupId":"OG001","value":"260"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to the date of death. If the participant had not died, survival was censored on last date the participant was known to be alive.","groups":[{"description":"Tablets, oral, dasatinib 100 mg once daily (QD)","id":"OG000","title":"Dasatinib"},{"description":"Tablets, oral, imatinib 400 mg once daily (QD)","id":"OG001","title":"Imatinib"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"Participants were followed-up for at least 5 years","title":"Percentage of Participants With Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}